UPPER GASTROINTESTINAL LESIONS AFTER POTASSIUM CHLORIDE SUPPLEMENTS: A CONTROLLED CLINICAL TRIAL

F. Gilbert Mcmahon, Kemal Akdamar, Jerome R. Ryan, Atilla Ertan

Research output: Contribution to journalArticle

58 Scopus citations

Abstract

Liquid and solid formulations of potassium chloride (KCl) are widely used clinically. Enteric coated KCl preparations have occasionally produced intestinal ulceration, haemorrhage, obstruction, or even death. They were withdrawn from the market in 1965. Subsequently, wax-matrix slow-release KCl tablets were developed. Although these products were considered safe, gastrointestinal complications such as ulceration, haemorrhage, obstruction, and perforation have been reported. The effects of a new microencapsulated potassium chloride formulation on upper gastrointestinal tract mucosa was compared with that of a popular wax-matrix formulation in 48 healthy volunteers. After a week of KCl, subjects were gastroscoped, the endoscopist being blind to the type of preparation taken. Wax-matrix formulations were associated with a higher incidence of upper gastrointestinal lesions. The lesions were not accompanied by epigastric symptoms. Glycopyrrolate, given to some volunteers to decrease gastric emptying, aggravated the effects of potassium chloride.

Original languageEnglish (US)
Pages (from-to)1059-1061
Number of pages3
JournalThe Lancet
Volume320
Issue number8307
DOIs
StatePublished - Nov 13 1982

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'UPPER GASTROINTESTINAL LESIONS AFTER POTASSIUM CHLORIDE SUPPLEMENTS: A CONTROLLED CLINICAL TRIAL'. Together they form a unique fingerprint.

Cite this